Scientific deep-dive

Does Semaglutide Lower Inflammation? The hsCRP Evidence

Semaglutide 2.4 mg cut the inflammation marker hsCRP by about 38% versus placebo in SELECT, with the drop starting before major weight loss. What that may explain about heart benefit, and what a single blood marker cannot show.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
8 min read·11 citations

Semaglutide lowers high-sensitivity C-reactive protein (hsCRP), a blood marker of inflammation: in the SELECT trial, weekly semaglutide 2.4 mg reduced it by 37.8% relative to placebo at 104 weeks in people with cardiovascular disease and overweight or obesity but no diabetes[1]. Whether that means “less inflammation” in a broader sense, and whether it explains the drug’s heart benefit, are narrower questions with less certain answers. The SELECT authors’ modeling points to a partial role, and they state that hsCRP is a biomarker and not itself a pathogenic mediator[1].

What hsCRP measures, and why cardiologists track it

CRP rises downstream of interleukin-6 signaling, which makes it a convenient readout of an inflammatory pathway. Levels below 1 mg/L, from 1 to 3 mg/L, and above 3 mg/L are the conventional bands for low, intermediate and high relative cardiovascular risk, read alongside traditional risk factors[3].

Its appeal is prognostic. In a collaborative analysis of 31,245 statin-treated patients from three randomized trials, the highest hsCRP quartile compared with the lowest carried an adjusted hazard ratio of 1.31 for major adverse cardiovascular events (MACE), 2.68 for cardiovascular death and 2.42 for all-cause death. The matching LDL cholesterol figures were 1.07, 1.27 and 1.16[9]. That is an association, and it says nothing about what happens when a drug moves the number.

CANTOS came closer to that test. In 10,061 people with a prior heart attack and hsCRP of at least 2 mg/L, the antibody canakinumab 150 mg every 3 months lowered hsCRP by a median 37 percentage points more than placebo at 48 months, without lowering lipids, and reduced the primary cardiovascular endpoint (hazard ratio 0.85, 95% CI 0.74 to 0.98). It also came with more fatal infections, and the trial was funded by Novartis[10]. CANTOS supports the broad idea that targeting inflammation can reduce events. Canakinumab blocks a different target from semaglutide, so it does not show the two drugs work the same way.

What SELECT found

SELECT randomized 17,604 people to semaglutide 2.4 mg or placebo. At a mean 39.8 months of follow-up, MACE occurred in 6.5% and 8.0% respectively (hazard ratio 0.80, 95% CI 0.72 to 0.90)[2]. The hsCRP analysis was a prespecified secondary analysis; Novo Nordisk funded the trial and several authors are its employees[1].

These patients were already well treated. Median baseline hsCRP was 1.87 mg/L on semaglutide and 1.80 mg/L on placebo, below the 2 mg/L threshold guidelines use for residual inflammatory risk, and 88% took statins. Even so, geometric mean hsCRP fell 37.8% relative to placebo (95% CI −39.7 to −35.9) at 104 weeks. That estimate comes from in-trial data, counting people with a measurement whether or not they were still on treatment at week 104[1].

Baseline hsCRP also sorted people by risk. Across both arms, a level of 10 mg/L or more, compared with below 2 mg/L, carried hazard ratios of 2.17 for MACE, 3.94 for cardiovascular death and 3.40 for all-cause death. Semaglutide’s reduction in events was similar in size across baseline hsCRP groups (all interaction P values above 0.05), so a low starting value did not predict a smaller benefit[1].

The same direction across semaglutide trials

Results from the STEP program point the same way. At 68 weeks, semaglutide 2.4 mg lowered CRP relative to placebo by 44% in STEP 1, 39% in STEP 2, and 48% in STEP 3, using the treatment policy estimand; these were exploratory analyses, funded by Novo Nordisk[3]. In heart failure with preserved ejection fraction and obesity, CRP changed by −43.5% with semaglutide and −7.3% with placebo at 52 weeks (estimated treatment ratio 0.61, 95% CI 0.51 to 0.72)[4]; our STEP-HFpEF review covers that trial’s symptom results. A 2026 meta-analysis of nine placebo-controlled trials and 6,239 adults without diabetes pooled the CRP change at −40.90% (95% CI −46.37 to −35.42)[5]. Two of its five authors report financial ties to Novo Nordisk.

Semaglutide 2.4 mg versus placebo: CRP or hsCRP change. Populations and durations differ, so these rows should not be ranked.
TrialPopulationTimepointChange vs placeboAnalysis
SELECTCardiovascular disease, overweight or obesity, no diabetes104 weeks−37.8% (95% CI −39.7 to −35.9)In-trial data, regardless of treatment status
STEP 1Overweight or obesity, no type 2 diabetes68 weeks−44% (95% CI −49 to −39)Treatment policy estimand
STEP 2Overweight or obesity with type 2 diabetes68 weeks−39% (95% CI −46 to −30)Treatment policy estimand
STEP 3Overweight or obesity, no type 2 diabetes68 weeks−48% (95% CI −55 to −39)Treatment policy estimand
STEP-HFpEFHeart failure with preserved ejection fraction, BMI 30 or higher52 weeksEstimated treatment ratio 0.61 (95% CI 0.51 to 0.72)Not stated in the abstract

The dose question is less settled. STEP 2 also tested 1.0 mg. Measured from each group’s own baseline (not against placebo, which is the 39% in the table above), CRP fell 49% on 2.4 mg and 42% on 1.0 mg, and the gap between the two doses did not reach statistical significance (P = 0.06)[3].

The drop starts early and also appears with little weight loss

The most striking SELECT detail is timing. Among 6,011 randomized European patients with extra blood draws, hsCRP was down 12% at 4 weeks and 19% at 8 weeks on semaglutide, when weight loss was only 1.4% and 2.8%. On placebo at those points, hsCRP moved −1.8% and +0.1%. At week 8 people had reached only the 0.5 mg step of dose escalation[1].

People who barely lost weight also saw a change. Among those losing less than 2% of body weight by week 104, the ratio of hsCRP to baseline was 0.88 on semaglutide and 1.02 on placebo (estimated treatment ratio 0.86, 95% CI 0.81 to 0.91). Among those who gained weight, the ratios were 0.85 and 1.06[1].

Weight still counts. On semaglutide, the ratio fell in steps from 0.82 with under 5% weight loss to 0.66, 0.54 and 0.43 at 5% to under 10%, 10% to under 15%, and 15% or more[1]. The early and no-weight-loss findings suggest something beyond the scale. They do not prove a direct drug effect, because grouping people by what happened after randomization gives up the protection of the randomized comparison. The authors describe the weight categories as nonrandomized subgroups[1]. Cell and imaging work on how these drugs may act on arteries is covered in our vascular mechanism review.

Does the CRP drop explain the heart benefit?

Only in part, and the modeling is suggestive. When changes in hsCRP over time were added to the analysis, the MACE hazard ratio moved from 0.80 (95% CI 0.72 to 0.89) to 0.86 (95% CI 0.77 to 0.96). The authors characterize hsCRP changes as marking an effect contribution of 32% for MACE, 42% for cardiovascular death and 45% for all-cause death, and note that several of these measures crossed the line of no effect. Their conclusion is cautious: the MACE reduction “may have partially involved a decrease in inflammation”[1].

A separate prespecified SELECT analysis estimated that 33% of the MACE benefit was mediated through waist reduction[8]; our review of SELECT’s secondary analyses walks through it. The 33% and 32% come from different models and should not be added together, because the two measures overlap: CRP reductions tracked reductions in waist circumference and body weight in the STEP trials[3]. The overlap is partial. In the semaglutide arm of SELECT, the correlation between weight change and hsCRP change at week 104 was 0.266[1].

The authors’ own limits

The SELECT paper states that hsCRP is a single biomarker, that no adjustment was made for multiple comparisons, that the trial was not a weight-loss intervention, and that hsCRP can be altered by multiple factors[1].

Inflammation is more than one marker

A broader picture comes from 41 randomized trials of incretin drugs in type 2 diabetes. GLP-1 receptor agonists as a class lowered CRP or hsCRP (standardized mean difference −0.37, 95% CI −0.59 to −0.14) and raised adiponectin (0.30, 95% CI 0.13 to 0.46). Pooled effects on interleukin-6 (−0.14, 95% CI −0.37 to 0.10) and tumor necrosis factor alpha (−0.25, 95% CI −0.61 to 0.12) were not statistically significant, and heterogeneity was moderate to high. The authors call this a “selective” anti-inflammatory profile[6]. The STEP trials did not measure those cytokines at all[3].

Scale is a useful check too. In the phase 2 RESCUE trial of people with chronic kidney disease and hsCRP of at least 2 mg/L, the interleukin-6 antibody ziltivekimab cut median hsCRP by 77%, 88% and 92% across doses at 12 weeks, against 4% on placebo. That trial measured biomarkers and safety and was funded by Novo Nordisk[11]. Its population differs from SELECT’s, so this is context and not a comparison.

What about tirzepatide?

A post hoc SURMOUNT-1 analysis of 392 participants who completed treatment found hsCRP changes relative to placebo at 72 weeks of −36.9%, −46.9% and −54.6% on 5, 10 and 15 mg, and interleukin-6 changes of −25.4%, −27.8% and −30.2%. Several authors are affiliated with Eli Lilly[7]. In type 2 diabetes, two tirzepatide trials totaling 562 participants showed lower interleukin-6 but only a non-significant trend on CRP[6]. Because the SURMOUNT-1 sample includes completers only, and no head-to-head result is reported here, these figures cannot rank tirzepatide against semaglutide.

What to raise with a prescriber

  • Is an hsCRP test useful for you? The SELECT authors suggest it may help clinicians identify ongoing cardiovascular risk in patients with obesity and established disease[1]. None of the papers reviewed here tested adjusting semaglutide to an hsCRP target.
  • Do you expect relief from an inflammatory condition? These analyses measured a blood marker. A lower number does not establish that joint pain, swelling or another inflammatory symptom will improve.
  • How are you tolerating the drug? In SELECT, adverse events led to permanent discontinuation in 16.6% on semaglutide and 8.2% on placebo[2]. Keep that trade-off in the conversation, along with statins and your other heart medications.

Our reviews

Providers that offer semaglutide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

It lowers CRP and hsCRP, the blood markers most often reported in this research. In the SELECT trial, semaglutide 2.4 mg reduced hsCRP by 37.8% relative to placebo at 104 weeks. Whether it lowers inflammation more broadly is less clear, since a meta-analysis across the GLP-1 class in type 2 diabetes did not find significant pooled changes in interleukin-6 or tumor necrosis factor alpha.
In a SELECT subgroup of 6,011 European patients with extra blood draws, hsCRP was down 12% at 4 weeks and 19% at 8 weeks on semaglutide, during dose escalation and before major weight loss. Across the whole trial, the ratio of hsCRP to baseline reached its low point at the 52-week measurement and stayed there at 104 weeks.
It may be part of the reason, but this has not been proven. SELECT modeling suggested hsCRP changes mark an estimated 32% contribution on major cardiovascular events, and the authors say the benefit may have partially involved less inflammation. hsCRP is a marker and not a cause of heart disease, and a separate analysis linked a similar share of the benefit to waist reduction.
In SELECT, people on semaglutide who lost less than 2% of body weight by week 104 had an hsCRP ratio to baseline of 0.88, compared with 1.02 on placebo. The drop was larger with more weight loss, reaching a ratio of 0.43 at 15% or more. These groups were defined after randomization, so they suggest an effect beyond weight loss without proving one.

References

  1. 1.Plutzky J, Bogdański P, Colhoun HM, et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation. 2026. PMID: 42610271.
  2. 2.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID: 37952131.
  3. 3.Verma S, Bhatta M, Davies M, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. EClinicalMedicine. 2023. PMID: 36467859.
  4. 4.Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023. PMID: 37622681.
  5. 5.Milluzzo A, Oteri V, Manuella L, et al. Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis. Int J Obes (Lond). 2026. PMID: 42668312.
  6. 6.Kanbay M, Shah E, AlShiab R, et al. Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2026. PMID: 42449480.
  7. 7.Sattar N, Linetzky B, Ruotolo G, et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. J Am Coll Cardiol. 2026. PMID: 42233927.
  8. 8.Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025. PMID: 41138739.
  9. 9.Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023. PMID: 36893777.
  10. 10.Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017. PMID: 28845751.
  11. 11.Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021. PMID: 34015342.

Does a GLP-1 Affect Blood Pressure? Lower, Higher, or Both — The Evidence

GLP-1s lower systolic blood pressure by about 5-7 mmHg on average, through weight loss and direct vascular effects; a small subset sees dose-dependent heart-rate increases. Evidence from STEP-1, SURMOUNT-1, SELECT and drug interactions.

11 min read

Does Semaglutide Help You Live Longer? Longevity, Mortality and Aging Evidence

In randomized trials, deaths from any cause were about 20% lower on semaglutide in people with heart or kidney disease. What SELECT, FLOW and SOUL show, the early aging-clock and mouse lifespan data, and where longevity hype goes too far.

8 min read

SELECT Trial: Beyond MACE - Secondary Endpoints (2026)

SELECT's prespecified secondary analyses: semaglutide cut a kidney composite 22%, helped heart failure across HFpEF and HFrEF, and held 10.2% weight loss 4 years.

13 min read

GLP-1 and HFrEF Heart Failure: The Evidence (2026)

GLP-1 drugs help in HFpEF, but the randomized HFrEF trials (FIGHT, LIVE) of liraglutide showed no benefit, a faster heart rate, and possible harm signals.

12 min read

Do GLP-1 Drugs Like Ozempic and Mounjaro Lower Stroke Risk? The Evidence

GLP-1 drugs probably lower ischemic stroke risk modestly in type 2 diabetes, by about 12–16% in trial meta-analyses, with the benefit growing over time. A stroke benefit hasn't been shown without diabetes. What the trials and 2026 studies show, and who benefits.

9 min read

Ozempic and Heart Rate: Why Semaglutide Raises Your Pulse (and What It Means) (2026)

Ozempic (semaglutide) raises resting heart rate slightly, about 1-4 bpm on average, a labeled class effect. SUSTAIN-6 and SELECT still showed fewer cardiovascular events. How to tell a normal pulse rise from palpitations, and the red flags to report.

8 min read

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $79/mo

“starting at” price

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $79/mo

sale price

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo

starting dose

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →